CoChat

AI-Aided Design of Novel Targeted Covalent Inhibitors against SARS-CoV-2

Open access
Tang, Bowen, He, Fengming, Liu, Dongpeng, He, Fei, Wu, Tong, Fang, Meijuan, Niu, Zhangming, Wu, Zhen, Xu, Dong · 2022 · Biomolecules
Cited by 144

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

The drug repurposing of known approved drugs (e.g., lopinavir/ritonavir) has failed to treat SARS-CoV-2-infected patients. Therefore, it is important to generate new chemical entities against this virus. As a critical enzyme in the lifecycle of the coronavirus, the 3C-like main protease (3CLpro or Mpro) is the most attractive target for antiviral drug design. Based on a recently solved structure (PDB ID: 6LU7), we developed a novel advanced deep Q-learning network with a fragment-based drug design (ADQN–FBDD) for generating potential lead compounds targeting SARS-CoV-2 3CLpro. We obtained a series of derivatives from the lead compounds based on our structure-based optimization policy (SBOP). All of the 47 lead compounds obtained directly with our AI model and related derivatives based on the SBOP are accessible in our molecular library. These compounds can be used as potential candidates by researchers to develop drugs against SARS-CoV-2.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/biom12060746

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 144

Metadata

Authors
Tang, B., He, F., Liu, D., He, F., Wu, T., Fang, M., Niu, Z., Wu, Z., & Xu, D.
Venue
Biomolecules
Publisher
MDPI AG
Published
2022-05-25
Volume
12
Issue
6
Pages
746
ISSN
2218-273X (ISSN-L)
OpenAlex
W4281570112
Cited by
144
References
6
FWCI
7.35
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: AI-Aided Design of Novel Targeted Covalent Inhibitors against SARS-CoV-2. https://app.cochat.ai/papers/10.3390/biom12060746
The paper
Tang, B., He, F., Liu, D., He, F., Wu, T., Fang, M., Niu, Z., Wu, Z., & Xu, D. (2022). AI-Aided Design of Novel Targeted Covalent Inhibitors against SARS-CoV-2. Biomolecules. https://doi.org/10.3390/biom12060746

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.